APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attention Deficit Hyperactivity Disorder (ADHD) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025180 pages

Choose your research edition.

Industry ResearchAttention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Attention Deficit Hyperactivity Disorder (ADHD) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Attention Deficit Hyperactivity Disorder (ADHD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Attention Deficit Hyperactivity Disorder (ADHD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attention Deficit Hyperactivity Disorder (ADHD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Attention Deficit Hyperactivity Disorder (ADHD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Attention Deficit Hyperactivity Disorder (ADHD) Drugs include Celltech Group, Perdue Pharma, Glaxosmith Kline, Eli Lilly, Novartis, Johnson & Johnson, Takeda and Janssen Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Attention Deficit Hyperactivity Disorder (ADHD) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Attention Deficit Hyperactivity Disorder (ADHD) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Attention Deficit Hyperactivity Disorder (ADHD) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Attention Deficit Hyperactivity Disorder (ADHD) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Segment by Company

Celltech Group

Perdue Pharma

Glaxosmith Kline

Eli Lilly

Novartis

Johnson & Johnson

Takeda

Janssen Pharmaceuticals, Inc.

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Segment by Type

Stimulants

Non-Stimulants

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Segment by Application

Adolescent

Pediatric

Adults

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention Deficit Hyperactivity Disorder (ADHD) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attention Deficit Hyperactivity Disorder (ADHD) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention Deficit Hyperactivity Disorder (ADHD) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Attention Deficit Hyperactivity Disorder (ADHD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Attention Deficit Hyperactivity Disorder (ADHD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Attention Deficit Hyperactivity Disorder (ADHD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Trends Table 2. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Drivers Table 3. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Opportunities and Challenges Table 4. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Restraints Table 5. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Manufacturers Table 9. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Manufacturers, Product Type & Application Table 13. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Stimulants Table 17. Major Manufacturers of Non-Stimulants Table 18. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type (2021-2026) & (k units) Table 20. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type (2027-2032) & (k units) Table 21. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Type (2021-2026) Table 22. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Type (2027-2032) Table 23. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type (2021-2026) & (k units) Table 25. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type (2027-2032) & (k units) Table 26. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Adolescent Table 29. Major Manufacturers of Pediatric Table 30. Major Manufacturers of Adults Table 31. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application (2021-2026) & (k units) Table 33. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application (2027-2032) & (k units) Table 34. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Application (2021-2026) Table 35. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Application (2027-2032) Table 36. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application (2021-2026) & (k units) Table 38. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application (2027-2032) & (k units) Table 39. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Application (2021-2026) Table 40. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Application (2027-2032) Table 41. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Region (2021-2026) & (k units) Table 43. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Region (2021-2026) Table 44. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2026) & (k units) Table 48. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2027-2032) & (k units) Table 49. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2026) & (k units) Table 51. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2027-2032) & (k units) Table 58. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Region (2021-2026) Table 62. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Region (2027-2032) Table 63. Celltech Group Company Information Table 64. Celltech Group Business Overview Table 65. Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 67. Celltech Group Recent Development Table 68. Perdue Pharma Company Information Table 69. Perdue Pharma Business Overview Table 70. Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 72. Perdue Pharma Recent Development Table 73. Glaxosmith Kline Company Information Table 74. Glaxosmith Kline Business Overview Table 75. Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 77. Glaxosmith Kline Recent Development Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 82. Eli Lilly Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 87. Novartis Recent Development Table 88. Johnson & Johnson Company Information Table 89. Johnson & Johnson Business Overview Table 90. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 92. Johnson & Johnson Recent Development Table 93. Takeda Company Information Table 94. Takeda Business Overview Table 95. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 97. Takeda Recent Development Table 98. Janssen Pharmaceuticals, Inc. Company Information Table 99. Janssen Pharmaceuticals, Inc. Business Overview Table 100. Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio Table 102. Janssen Pharmaceuticals, Inc. Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Distributors List Table 106. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Image Figure 2. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales (2021-2032) & (k units) Figure 5. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Stimulants Image Figure 9. Non-Stimulants Image Figure 10. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Type (2021-2032) Figure 16. Adolescent Image Figure 17. Pediatric Image Figure 18. Adults Image Figure 19. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Application (2021-2032) Figure 22. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Country (2021-2032) Figure 39. China Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulants
  • Non-Stimulants
Applications
  • Adolescent
  • Pediatric
  • Adults
Companies covered
  • Celltech Group
  • Perdue Pharma
  • Glaxosmith Kline
  • Eli Lilly
  • Novartis
  • Johnson & Johnson
  • Takeda
  • Janssen Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Dynamics
  1. 2.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Trends
  2. 2.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Drivers
  3. 2.3 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Opportunities and Challenges
  4. 2.4 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Restraints
3 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Manufacturers
  1. 3.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Tier 1, Tier 2, and Tier 3
4 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Type
  1. 4.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Type Introduction
  2. 4.1.1 Stimulants
  3. 4.1.2 Non-Stimulants
  4. 4.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type
  5. 4.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type
  9. 4.3.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Type (2021-2032)
5 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Application
  1. 5.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Application Introduction
  2. 5.1.1 Adolescent
  3. 5.1.2 Pediatric
  4. 5.1.3 Adults
  5. 5.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application
  6. 5.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application
  10. 5.3.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Application (2021-2032)
6 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Region
  1. 6.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region
  1. 7.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region
  2. 7.1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Attention Deficit Hyperactivity Disorder (ADHD) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Celltech Group
  2. 8.1.1 Celltech Group Company Information
  3. 8.1.2 Celltech Group Business Overview
  4. 8.1.3 Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Celltech Group Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  6. 8.1.5 Celltech Group Recent Developments
  7. 8.2 Perdue Pharma
  8. 8.2.1 Perdue Pharma Company Information
  9. 8.2.2 Perdue Pharma Business Overview
  10. 8.2.3 Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Perdue Pharma Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  12. 8.2.5 Perdue Pharma Recent Developments
  13. 8.3 Glaxosmith Kline
  14. 8.3.1 Glaxosmith Kline Company Information
  15. 8.3.2 Glaxosmith Kline Business Overview
  16. 8.3.3 Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Glaxosmith Kline Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  18. 8.3.5 Glaxosmith Kline Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Takeda
  38. 8.7.1 Takeda Company Information
  39. 8.7.2 Takeda Business Overview
  40. 8.7.3 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  42. 8.7.5 Takeda Recent Developments
  43. 8.8 Janssen Pharmaceuticals, Inc.
  44. 8.8.1 Janssen Pharmaceuticals, Inc. Company Information
  45. 8.8.2 Janssen Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Janssen Pharmaceuticals, Inc. Attention Deficit Hyperactivity Disorder (ADHD) Drugs Product Portfolio
  48. 8.8.5 Janssen Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Value Chain Analysis
  2. 9.1.1 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Production Mode & Process
  6. 9.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Distributors
  9. 9.2.3 Attention Deficit Hyperactivity Disorder (ADHD) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst